Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: 3 - Caught on Camera

Moderna Shares Double Overnight Because a Made-to-Order mRNA Vaccine Actually Beats Skin Cancer

Moderna's personalised mRNA cancer vaccine, intismeran, significantly reduces melanoma recurrence in a Phase 3 trial, doubling the company's stock value and marking a milestone in cancer treatment.

International Business Times UK · Aug 19

Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test

Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment

The Independent UK · Aug 19

Possible Skin Cancer Vaccine Shows Promise In Late Stage Trial. Moderna Stock Skyrockets.

The late-stage clinical trial was described as a "landmark moment."

International Business Times · Aug 19

From analysis to the latest developments in health,
read the most diverse news in one place.

Moderna shares soar 159% in a day after cancer vaccine succeeds in late-stage trial

Moderna shares surged after its personalized mRNA cancer vaccine trial showed positive results. The treatment, combined with Keytruda, reduced melanoma recurrence and spread significantly. This marks the first successful late-stage trial for an mRNA cancer vaccine. The findings offer hope for future growth beyond COVID-19 vaccines. Discussions with regulators are…

The Economic Times · Aug 19

US stocks: US market regains ground as bond yields ease; healthcare stocks rally

Major stock indexes recovered on Wednesday after a prior day's decline. Moderna shares surged significantly following positive cancer therapy trial results. Government bond yields eased from highs, boosting investor risk appetite. Retailers like Target and Lowe's reported quarterly results, influencing consumer spending views. Geopolitical developments and Federal Reserve minutes remained…

The Economic Times · Aug 19

Skin cancer breakthrough after experimental mRNA drug found to prevent disease returning

More than 8,500 Americans are expected to die of melanoma this year

The Independent UK · Aug 19

Merck Puts a Decade Timeline on the MMR Split Order as Single Disease Shots Remain Unlicensed

Merck and GSK say separate measles, mumps, and rubella shots could take up to a decade to reach US pediatric offices. What families face now.

Medical Daily · Aug 17

Read news from The Economist, FT, and more,
with one subscription

Trump’s vaccine overhaul could bring more shots, higher costs for US families

President Donald Trump's vaccine plan faces significant financial and logistical hurdles. Drugmakers must develop new manufacturing processes and conduct extensive clinical studies. Separating vaccines could lead to more appointments and increased costs for families. Public health experts question the scientific basis for the proposed changes. States retain authority to mandate…

The Economic Times · Aug 13

Trump's vaccine plan would require millions of individual shots last used decades ago

The biggest obstacles to President Donald Trump’s order on vaccines may be the logistical challenges it poses for U.S. parents, health providers and drugmakers

The Independent UK · Aug 13

Executive order on vaccines bypasses an evidence-based process that has kept kids safe

President Donald Trump signed an executive order on Aug. 10, 2026, calling for the combined measles, mumps and rubella vaccine to be given as three separate shots at three separate appointments. The combined MMR vaccine is currently given at 12 to 15 months of age and again between ages 4…

The Conversation · Aug 12

Weekly HIV Pill Held Viral Suppression as Well as Daily Therapy in Phase 3 Trial

A once-weekly HIV pill matched daily therapy for viral suppression in a phase 3 trial. It is not approved yet. Here is what the data show.

Medical Daily · Aug 7

Merck & Co’s Stock: Analyst Estimates & Ratings

Merck has outperformed the broader market over the past year, and analysts remain optimistic about the stock.

Barchart · Aug 6

Once-Weekly HIV Pill Held Viral Suppression as Well as Daily Treatment in Two Phase 3 Trials

Two phase 3 trials found that a weekly islatravir and lenacapavir tablet matched daily HIV therapy at 48 weeks. Here is what the data show.

Medical Daily · Aug 5

Africa CDC Moves to Test Merck's Licensed Ebola Vaccine Against Bundibugyo as Congo Outbreak Becomes Country's Largest

Africa CDC plans to ask WHO advisers to allow testing of Ervebo against Bundibugyo Ebola. No trial is approved, and no protection is proven.

Medical Daily · Aug 4

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart · Aug 2

Earnings, PMI and Other Key Things to Watch this Week

Markets enter an earnings-dominated week with a huge concentration of corporate results spanning technology, industrials, healthcare, consumer discretionary, and entertainment sectors. This will provide a critical assessment of economic health and corporate fundamentals amid persistent uncertainty about technology sector valuations and AI infrastructure spending.

Medical Daily · Jul 29

Stockpiled Ebola Vaccines Produced an Antibody Response Against the Strain Driving the Congo Outbreak

New NEJM data show licensed Zaire Ebola vaccines produce some antibody response against Bundibugyo, the strain behind the record Congo outbreak.

Medical Daily · Jul 27

FDA Approves the First Oral PCSK9 Inhibitor, Ending the Injection-Only Era for a Major Cholesterol Drug Class

FDA approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor for adults with high LDL cholesterol. What it changes and what remains unknown.

Medical Daily · Jul 24

FDA Expands Keytruda Approval to All Bladder Cancer Patients Before Surgery, Not Just Those Avoiding Chemo

The FDA expanded Keytruda plus Padcev to all muscle-invasive bladder cancer patients on July 10, 2026. Here is who now qualifies and what the KEYNOTE-B15 trial showed.

Get all your
news in one place.

100's of premium titles.
One news app.

Medical Daily · Jul 20

FDA Approves Lipfendra, the First Oral PCSK9 Inhibitor: A Once-Daily Pill That Cuts LDL Cholesterol as Well as Injectables

FDA approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, on July 16, 2026. The once-daily pill cut LDL by up to 59% in trials. Here's who it's for.

Kiplinger · Jul 16

Nasdaq Sinks as Chip Stocks Drop Again: Stock Market Today

While Taiwan Semi's post-earnings drop pressured chipmakers, healthcare names outperformed thanks to Merck's FDA win and Eli Lilly's big buy.

The Economic Times · Jul 16

Merck gets US FDA nod for first-in-its-class oral cholesterol drug

The U.S. FDA has approved Merck's new cholesterol-lowering pill, Lipfendra. This oral medication works by blocking the PCSK9 protein, which helps lower bad cholesterol. Lipfendra offers an alternative for patients who dislike injectable treatments for heart disease. The drug is priced at $10.50 daily and will be available soon. Merck…

The Independent UK · Jul 16

FDA approves a first-of-its-kind pill to cut cholesterol in high-risk patients

The Food and Drug Administration has approved a first-of-its-kind pill that can drastically reduce cholesterol

The Guardian - US · Jul 16

Drugmaker Merck announces approval of new cholesterol-fighting drug

Lipfendra can be taken in conjunction with or an alternative to statins, the most prescribed medication in the US

International Business Times · Jul 16

FDA Clears First Of Its Kind Cholesterol Medication: Lipfendra Makes History

The U.S. Food and Drug Administration has approved Merck's Lipfendra (enlicitide), making it the first oral PCSK9 inhibitor available in the United States and offering millions of patients with high cholesterol a new alternative to injectable therapies.

Bored Panda · Jul 15

Hair Transplants Carry A Life-Changing Risk That Nobody Is Talking About

For many people, a hair transplant feels like the end of a long battle with hair loss. But the medication often recommended afterward has become the center of an increasingly bitter medical debate. This investigation examines what clinics tell patients, what regulators now warn, and why some experts believe informed…

1 2 3 4 5

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.